

RX.PA.038.MPC Zolgensma & Itivisma

The purpose of this policy is to define the prior authorization process for Zolgensma & Itivisma.

DEFINITIONS

Spinal Muscular Atrophy (SMA) – an autosomal recessive neuromuscular disease characterized by degeneration of the motor neurons in the anterior horn of the spinal cord, resulting in atrophy of the voluntary muscles of the limbs and trunk. Despite being a rare disease, SMA is a leading genetic cause of infant mortality and a major cause of childhood morbidity. It is attributed to deletions or mutations in the SMN1 gene (chromosome 5q13), causing insufficient expression of survival motor neuron (SMN) protein. The lack of SMN protein appears to result in dysfunction and eventual death of motor neurons. SMA can present clinically at any time from in utero to adulthood with gross motor function deficits, muscle weakness, and pulmonary disease due to neuromuscular weakness. Common complications include: difficulty feeding, swallowing, failure to thrive, loss of ambulation, scoliosis, joint contracture, pulmonary disease, and death

Spinal Muscular Atrophy Types I, II, III – Type I manifests around or before the patient is 6 months of age. The presentation may include: hypotonia, unable to control head movement, unable to sit without assistance. Type II has an onset between 6 to 18 months. Patients are generally able to sit independently, the ability to walk is usually not achieved without assistance. Type III manifests after the patient is 18 months of age or older. Patients may be able to walk without assistance or lose the ability to walk.

PROCEDURE

A. Initial Authorization Criteria:

Must meet all of the criteria listed below.

- Must be prescribed by a neurologist who specializes in the treatment of spinal muscular atrophy
- Must be prescribed at a dose within the manufacturer's dosing guidelines (based on diagnosis, weight, etc) listed in the FDA approved labeling
- Must have a diagnosis of spinal muscular atrophy (SMA)
 - Must have chart documentation of confirmatory genetic testing of bi-allelic mutations in the survival motor neuron 1 (SMN1) gene
- Must not have advanced SMA as evidenced by any of the following:
 - Permanent ventilator dependence (defined as at least 16 hours of respiratory assistance per day continuously for at least 14 days in the absence of an acute, reversible illness or a perioperative state)

- Complete paralysis of limbs
- For Zolgensma:
 - Must be less than 2 years of age
 - If born premature, must have reached corresponding full-term gestational age
- For Itvisma:
 - Must be at least 2 years of age or older
- Must have the following baseline testing completed (within 60 days of request):
 - Platelet count
 - Troponin-1
 - Liver function tests (ALT, AST, bilirubin, prothrombin time)
 - Anti-AAV9 (anti- adeno-associated virus serotype 9) antibodies titer $\leq 1:50$
- Must not have previously received treatment with Zolgensma or Itvisma
- Must not use concurrently with Spinraza
- Must plan to receive 30 days of systemic corticosteroids equivalent to oral prednisolone at 1 mg/kg beginning 1 day prior to treatment with Zolgensma or Itvisma

B. Must be prescribed at a dose within the manufacturer's dosing guidelines (based on diagnosis, weight, etc) listed in the FDA approved labeling.

C. Zolgensma and Itvisma will be considered investigational or experimental for any other use and will not be covered.

D. Reauthorization Criteria:

- No reauthorization allowed

LIMITATIONS

Length of Authorization (if above criteria met)	
Initial Authorization	1-time approval per lifetime **Please notify DOP PRIOR to approving.**
Reauthorization	This medication is only indicated for one time use so reauthorizations will not be granted.
Quantity Limit	
Zolgensma	• Weight based dosing- 1.1×10^{14} vector genomes (vg) per kg • Max of 9 vials

Itvisma	1 vial – 1.2×10^{14} vector genomes
---------	---

HCPCS CODES

Code	Description
J3399	Inj AVSX-101-XIOI P-TX TO 5×10^{15} VG
J3405	Injection, onasemnogene abeparvovec-brve, per treatment

REFERENCES

1. Zolgensma [prescribing information]. Bannockburn, IL; AveXis, 2019.
2. Itvisma [prescribing information]. Bannockburn, IL; Novartis Gene Therapies, Inc., 2025

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
<i>New Policy</i>	08/19
<i>Aligned diagnosis requirements with PI- 11/19</i>	N/A
<i>Annual Review</i>	02/20, 03/21, 02/2022
<i>Addition of weight-based dosing criteria</i>	03/20
<i>Updated client applicability</i>	12/20
<i>P&T Review</i>	05/21
<i>Addition of dosing requirements and off-label restrictions</i>	12/2021
<i>Annual Review</i>	02/2023
<i>Annual Review</i>	02/2024
<i>Annual Review</i>	02/2025
<i>Annual Review</i>	02/2026
<i>Selected Revision Addition of Itvisma</i>	06/2026